Health Condition 1: O908- Other complications of the puerperium, not elsewhere classified
Conditions
Interventions
Intervention1: Nil: Nil
Control Intervention1: This is observational trial: This is observational trial
Sponsors
Indian Council of Medical Research
Eligibility
Inclusion criteria
Inclusion criteria: 1. Women over 18 years of age. 2. Diagnosed with hypertension during pregnancy (preeclampsia and gestational hypertension).
Exclusion criteria
Exclusion criteria: 1. History of chronic kidney disease, heart disease, diabetes with renal involvement or vasculopathy. 2. Pregnancy with chronic hypertension, other pre-existing medical conditions or history of illicit drug use. 3. Intervention that could modify the outcome like aspirin use.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1. We expect from this study to see the trend of inflammatory and biochemical markers in post delivery HDP women and to early predict risk factor of CVD later in life. 2. We expect that in this study to find, there is any difference between normalization of raised inflammatory marker and difference in biochemical marker 3. We will also do non invasive test (ETCO levels) and see the correlation with biomarkers. We hope to use these markers as screening tool for triaging women. 4. Most of these markers are assessed during antenatal period and very few studies are done in postpartum period. Of these sFlt1 and hCRP are specifically and strongly associated with development of CVD later in life. 5. Women who had hypertensive disorder in pregnancy with altered inflammatory markers may differentiate women at risk of developing hypertension a precursor of CVD later in life Timepoint: 1. We expect from this study to see the trend of inflammatory and biochemical markers in post delivery HDP women and to early predict risk factor of CVD later in life. 2. We expect that in this study to find, there is any difference between normalization of raised inflammatory marker and difference in biochemical marker 3. We will also do non invasive test (ETCO levels) and see the correlation with biomarkers. We hope to use these markers as screening tool for triaging women. 4. Most of these markers are assessed during antenatal period and very few studies are done in postpartum period. Of these sFlt1 and hCRP are specifically and strongly associated with development of CVD later in life. 5. Women who had hypertensive disorder in pregnancy with altered inflammatory markers may differentiate women at risk of developing hypertension a precursor of CVD later in life | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. We expect from this study to see the trend of inflammatory and biochemical markers in post delivery HDP women and to early predict risk factor of CVD later in life. 2. We expect that in this study to find, there is any difference between normalization of raised inflammatory marker and difference in biochemical marker 3. We will also do non invasive test (ETCO levels) and see the correlation with biomarkers. We hope to use these markers as screening tool for triaging women. 4. Most of these markers are assessed during antenatal period and very few studies are done in postpartum period. Of these sFlt1 and hCRP are specifically and strongly associated with development of CVD later in life. 5. Women who had hypertensive disorder in pregnancy with altered inflammatory markers may differentiate women at risk of developing hypertension a precursor of CVD later in life Timepoint: 6 WEEK, 6 MONTHS AND 12 MONTHS | — |
Countries
India
Contacts
Public ContactDr Garima Kachhawa
All India Institute of Medical Sciences, New Delhi
Outcome results
None listed